Top Biotech Companies in Vancouver (49)
HTuO Biosciences is a deep tech company, working at the interface of chemistry, physics and computer programming, to develop an advanced molecular simulation capable of accurately predicting the behaviour of molecules.
Levitt-Safety is a Canadian safety supplier serving workplaces nationwide. Its offerings include safety equipment, fire-protection solutions, environmental monitoring, worker training, and rental services. The company partners with organizations across Canada to support worker health and safety, providing products and services for fire prevention, workplace protection, and environmental risk management. Its nationwide network supports customers across multiple industries.
Dexcom Corporation is a pioneer and global leader in continuous glucose monitoring (CGM). Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started. We are broadening our...
Dexcom's Top Stability & Growth Strengths
Strong Market Position & Advantage: Dexcom is repeatedly portrayed as a co-leader globally and the U.S. leader in CGM, supported by deep integrations with automated insulin delivery systems and a durable duopoly structure. This positioning reflects sustained adoption of its G7 platform and scale advantages.
Strong Revenue Growth: Recent results and guidance indicate consistent double-digit year-over-year growth with expanding margins. Management communications highlight ongoing momentum into 2026 supported by continued platform rollouts.
Market Expansion: The launch of an over-the-counter sensor and extended-wear G7 broaden addressable users beyond intensive insulin therapy. International uptake and clinical data in non‑insulin type 2 populations further extend the growth runway.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
Quadra is a North American business-to-business distributor of chemicals and ingredients. Founded in 1976, it has grown into a 650-plus-employee organization serving customers across North America. The company combines product distribution with market and service expertise, supporting food and nutrition, industrial applications, and human-health sectors. Quadra emphasizes customer service, innovation, employee development, and continued growth for its partners and customers...
LifeLabs is a Canadian healthcare company providing laboratory diagnostic services and digital health connectivity systems. Its testing helps patients and healthcare practitioners diagnose, treat, monitor, and prevent disease. The company operates community, specialty, genetic, and at-home testing services, including Canada’s largest online patient portal. LifeLabs processes more than 112 million laboratory tests annually and serves millions of Canadians through over...
Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.
Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid...
Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline...
adMare BioInnovations is a Canadian life-sciences company-creation organization that identifies promising research and helps turn it into globally competitive companies. It supports early-stage ventures with seed capital, commercial research and development, intellectual-property and business-development expertise, specialized lab facilities, and talent and leadership programs. It also helps existing life-sciences businesses scale, strengthens Canada's innovation ecosystem, and reinvests returns into the domestic...
WEX Pharmaceuticals Inc. is a late-stage drug development company in Vancouver, Canada dedicated to the research, development, manufacture, and commercialization of Halneuron®, a new novel non-opioid analgesic. Halneuron® is a highly selective sodium channel blocker and represents a breakthrough in painkiller technology: - Non-addictive, no withdrawal symptoms and no euphoria - No build of up of tolerance over time - A long duration of...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give...
Jazz Pharmaceuticals, Inc's Top Stability & Growth Strengths
Strong Market Position & Advantage: Jazz is described as a clear leader in rare sleep disorders through its oxybate franchise (Xywav/Xyrem and authorized generics royalties) and in cannabinoid-based epilepsy with Epidiolex surpassing $1B in 2025. Xywav’s idiopathic hypersomnia approval with orphan exclusivity and category-leading revenue reinforce defensibility.
Strong Revenue Growth: Record 2025 revenue around $4.27 billion and a record Q4, with 2026 guidance still pointing up, indicate sustained top-line momentum. Company communications highlight a multi-year streak of annual growth continuing into 2026.
Diversified Revenue Streams: A balanced base with rare sleep revenues above $2B, Epidiolex above $1B, and roughly $1.13B in oncology plus new contributions from Modeyso and royalties shows multiple revenue pillars. Pipeline drivers like zanidatamab and Zepzelca label expansion add additional avenues.
Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited...
BetterLife is an emerging biotech company focused on developing & commercializing patient-friendly compounds to address the global unmet mental health issues
We are a Vancouver, Canada-based biotech firm focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe in vivo delivery of active gene editing machinery into target tissues. We have secured the exclusive worldwide...
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life.
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel’s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are...
Cytel's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Private-equity ownership by Astorg and Nordic Capital is positioned as support to accelerate Cytel’s next phase of growth and innovation, signaling access to growth-oriented capital and sponsorship.
Product Line Growth: East Horizon launched as a cloud-based evolution of Cytel’s trial-design software and has continued adding modules through 2025, indicating ongoing investment and expansion of the software offering.
Market Expansion: Multiple acquisitions in 2022–2023 (e.g., Stève Consultants and co.faktor) and an increase in offices from 2021 to 2023 indicate broader geographic coverage and capability expansion, particularly across Europe.
Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API). #MadeBetter
Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design...
